ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Resmetirom (Rezdiffra)

Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).

Conditional
CHMP opinion 19 Jun 2025 → EU licence 18 Aug 2025 · Madrigal Pharmaceuticals EU Limited

Research

Gastroenterology · J Hepatol · 2026-09-29

EASL-EASD-EASO guidance recommends resmetirom or semaglutide, alongside lifestyle intervention, for adults with non-cirrhotic MASH and fibrosis stages 2-3; semaglutide may be preferred with obesity, T2D or cardiovascular risk. Not advised as MASH treatment in cirrhosis.

Guideline
European Association for the Study of Obesity (EASO). Electronic address: [email protected] EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.